Adam Bass, M.D.
Adam Bass is an associate member of the Broad Institute’s Cancer Program. He is also a physician/scientist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and an assistant professor of medicine at Harvard Medical School.
Bass researches the genomic underpinnings of gastrointestinal (GI) cancers – particularly stomach and esophageal carcinomas. The overarching goal of his lab is to leverage their expertise in cancer genomics, experimental/functional biology, and clinical medicine in the search for the underlying mechanisms and therapeutic vulnerabilities of these cancers.
Working closely with researchers from the Broad, Bass is co-chairing The Cancer Genome Atlas (TCGA) project to characterize the genomes of gastric and esophageal cancer. Bass and his team are working to define the genes and genetic alterations most likely involved in GI tumors, and then pursue those genes of interest in follow-up studies to determine their role in cancer development. Their aim is to identify potential targets for cancer therapeutics, and ultimately to translate those findings into new therapeutic approaches to test in clinical trials.
Bass received his B.A. from Amherst College and his M.D. from Duke University School of Medicine. He conducted his clinical training at Massachusetts General Hospital and Dana-Farber/Partners Cancer Center, and completed a postdoctoral fellowship in the lab of Broad senior associate member Matthew Meyerson. He was a recipient of a 2008 Young Investigator Award from the American Society of Clinical Oncology, and more recently received the American Gastroenterological Association’s Funderburg Research Award in Gastric Cancer Biology as well as a Doris Duke Foundation Clinical Scientist Development Award.